About Us

Cellbricks Therapeutics is a Berlin and Boston-based preclinical biotech company pioneering the future of regenerative medicine and longevity. Built on deep tech innovation, the company combines proprietary biofabrication technology with advanced biomaterials and human cells to develop implantable tissue grafts for clinical use. Cellbricks’ mission is to transform healthcare by restoring tissue function – reliably and at scale.

Team

Our team unites deep scientific, clinical and business expertise to bring life-saving tissue therapeutics into the clinic – backed by over 100 years of tissue engineering experience.

Leadership

Alexander Leutner
Co-CEO (Business) & Co-founder

Formerly founded, scaled & successfully exited deep-tech start-up to world market leader for industrial technology, Hexagon. 12 years building and leading teams in start-up and corporate settings.

Dr. Simon MacKenzie
Co-CEO (Therapeutic Programs)

Former CEO at RegenHU; CBO at Axol Bioscience; Director at Kyorin Pharmaceutical Co. 25 years leading biotech & pharma therapeutics teams across US, EU, Asia.

Dr. Kathy Kordy, MD
Chief Medical Officer

Former Head of Rare Disease Immunology, Johnson&Johnson; Executive Director, Late Development, Novartis; Pediatric gastro-hepatologist & clinical pharmacologist, UCLA & CHLA. 20 years experience as medic & drug developer, driving innovative therapies to new markets.

Dr. Tobias Lam
CTO & Co-founder

Creator of Cellbricks‘ bioprinting technology. 10 years experience of 3D-bioprinting, biomaterial formulation and 3D-Bioprinter development.

Michael Kring
CFO

Owner of High Tech Corporate Services, former Group CFO at BioNTech SE. 20 years experience in financial modelling and controlling.

Troy Dale
Chairman of the board

Former Head of Strategic Partnerships Unit, Novartis; Former Chief Marketing Officer Greater China, Sanofi. 30 years experience as pharmaceutical executive. History of strategic conceptualisation through to “on the ground” execution.

Therapeutic Program Leads

Meet the entire team

Alexander Thomas
Soft Tissue Program Lead & Co-founder

PhD on bioprinted vasculature. 10 years experience of 3D-bioprinting, tissue engineering and building vasculature.

Dr. Alicia Ruppelt
Liver Tissue Program Lead

Former R&D liver engineer at Life Tec Group; Researcher at Merck. 6 years experience of 3D-bioprinting & tissue engineering coupled with managerial industry expertise.

Selected Partners and Supporters

Alongside backing from our institutional investors, Cellbricks and its technology have received invaluable support from leading organizations and strategic collaborators.